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Abstract Liver X receptors (LXRs) are nuclear receptors that
regulate the metabolism of cholesterol and bile acids. Despite
information on the specificity of their natural ligands, oxysterols,
relatively little is known about the ligand binding site in LXRs.
The helix 3 region in the ligand binding domain (LBD) of
peroxisome proliferator-activated receptors (PPARs) has been
implicated in ligand entry. Sequence alignment of LXRs,
farnesoid X receptor (FXR), and PPARs identified the
corresponding helix 3 region in the LXRL LBD. Residues F268
and T272, which are conserved in all the aligned sequences and
only in LXRs and FXR, respectively, were replaced with alanine.
The effects of these mutations on ligand binding and receptor
activation were examined using an in vitro ligand binding assay
and a cell based reporter assay, respectively. The LXRL mutant
F268A did not bind ligand. In contrast, conversion of T272 to
alanine has no effect on ligand binding. By transiently expressing
a chimeric receptor containing Escherichia coli tetracycline
repressor (TetR) and LXRL LBD and a reporter with a TetR
binding site, we show that mutant F268A lost the ability to
activate transcription of the reporter, whereas mutant T272A
still has an activity similar to that of the wild-type LXRL. These
data, consistent with the findings in the in vitro ligand binding
assay and our 3D modeling, are the first study that identifies a
residue critical for ligand binding in LXRL. ß 2000 Federation
of European Biochemical Societies. Published by Elsevier Sci-
ence B.V. All rights reserved.
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1. Introduction
Liver X receptors (LXRs) are members of a nuclear recep-
tor superfamily that induce ligand dependent transcriptional
activation of target genes [1]. There are two subtypes of
LXRs, LXRK and LXRL. LXRK is preferentially expressed
in liver, small intestine, kidney and spleen [2,3]. In contrast,
LXRL expression is ubiquitous [4]. The genomic structure and
the promoter regions of the two LXR genes contain speci¢c
regulatory sites, which suggest that LXRs may have physio-
logical roles in the immune system [5].
Like other nuclear receptors, LXRs heterodimerize with
retinoid X receptor (RXR) for function [1]. However, LXRs
represent a subclass of permissive nuclear receptors, including
PPARs and FXR [1]. In this subclass, the RXR heterodimers
can be activated independently by either the RXR ligand, the
partner’s ligand, or synergistically by both [1]. LXRs are ac-
tivated by naturally occurring oxysterols and regulate the ex-
pression of target genes [6^8], including ATP binding cassette
transporter 1 (ABC1), ATP binding cassette transporter 8
(ABC8) and cholesterol ester transfer protein (CETP) [9^11].
These ¢ndings suggest that LXRs might regulate lipoprotein
metabolism, especially that of high density lipoprotein (HDL)
[9^11]. In addition, LXRK increases the expression of choles-
terol 7-K hydroxylase, the rate-limiting enzyme in bile acid
synthesis [12]. In LXRK knockout mice, there is an accumu-
lation of cholesterol esters and a de¢ciency in the conversion
of cholesterol to bile acids [13], suggesting that LXRK is re-
sponsible for bile acid synthesis. In addition, LXRL is ex-
pressed in the livers of these mice and did not compensate
for the loss of LXRK, suggesting that LXRL may have di¡er-
ent biological functions.
The two functional domains, including the N-terminal
DNA binding domain (DBD) and the C-terminal ligand bind-
ing domain (LBD), mediate the transcriptional activation
function of nuclear receptors [14]. The LBD has been the
focus of intense study since it determines ligand speci¢city
[15,16]. In contrast to PPARs in the same subclass [17,18],
LXR LBDs and the critical helical regions within the LBDs
have not been characterized. Among the 12 helices in the LBD
of PPARK, the carboxyl helices are required for heterodimer-
ization with RXR and the N-terminal helices are involved in
forming ligand binding pockets [15,16,19]. Interestingly, a sin-
gle substitution of Glu282 with glycine in helix 3 of mouse
PPARK altered the transcriptional response to ligands, sug-
gesting that helix 3 is important for ligand selectivity [17]. In
order to study ligand dependent activation of LXRL, we have
identi¢ed a region in LXRL LBD that corresponds to helix 3
in PPARs. We have examined the e¡ects of mutations within
this region on ligand binding and transcriptional activation by
LXRL. Our results provide evidence for the important role of
residue F268 in ligand binding by LXRL LBD.
2. Materials and methods
2.1. Materials
[3H]24(S)-hydroxycholesterol was synthesized by Amersham. Non-
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labeled 24(S)-hydroxycholesterol was synthesized by SH-ICON (Chi-
cago, IL, USA). The HisWBind protein puri¢cation kit was from No-
vagen. Scintillation proximity assay (SPA) beads were from Amer-
sham. Tissue culture media and transfection reagents were from
Gibco BRL. Restriction enzymes were from New England Biolabs
or Gibco BRL. Luciferase and L-galactosidase assay kits were from
Promega.
2.2. Vector construction, mutagenesis and protein expression
Human LXRL LBD containing amino acids 203^461 was ampli¢ed
by polymerase chain reaction. The 5P primer (CAT ATG CCT GGT
GGA TCT GAG GCA GGC) contains a NdeI site so that after
ligation, the LXRL LBD is in-frame with the initiation methionine
and the N-terminal HIS tag in the expression vector pET16b (Nova-
gen). The 3P primer (GGA TCC CCC TCA CTC GTG GAC GTC
CCA) contains a stop codon followed by a BamHI site for convenient
cloning. The expression vector pET-LXRL LBD was transformed into
Escherichia coli BL21 (DE3). Bacteria cultures were grown at 37‡C
until OC595 reached 0.5 and induced at room temperature with 50 WM
IPTG for 3 h. Lysates were prepared for direct SPA based ligand
binding assay [9,20] or protein puri¢cation according to the manufac-
turer’s instructions. Mutagenesis reaction was carried out using an
ExSite site directed mutagenesis kit (Stratagene). Protein puri¢cation
was carried out with a HisWBind protein puri¢cation kit (Novagen)
according to the manufacturer’s instruction manual.
2.3. SPA based ligand binding assay
An SPA based ligand binding assay on a 96 well plate format was
developed using [3H]24(S)-hydroxycholesterol, His-tagged protein and
copper-coated SPA beads. In each well of 96 well clear bottom plates
(Costar, Cornings, NY, USA), bacterial lysates or puri¢ed protein
were incubated with 200 nM [3H]24(S)-hydroxycholesterol in a ¢nal
volume of 100 Wl binding bu¡er (50 mM Tris^HCl, 10% glycerol, 10
mM sodium molybdate) at room temperature for 30 min. Beads bu¡er
(25% beads (v/v), 25% bovine IgG (v/v), 50% binding bu¡er (v/v)) was
added (50 Wl/well) and incubated for 30 min. The plates were set on a
bench for 10 min to allow the beads to settle on the bottom of the
plates before being counted on a L counter.
2.4. Gel electrophoresis and Western blotting
Samples were resolved electrophoretically on 4^20% gradient gels at
a constant voltage (100^180 V). Proteins were transferred to Immo-
bilon-P membranes using a semi-dry electroblotter. The membranes
were washed with TBST bu¡er (20 mM Tris^HCl, 137 mM NaCl,
0.5% Tween-20, pH 7.6), blocked in blocking bu¡er (TBST containing
5% dry milk) for 1 h at room temperature, and incubated with anti-
HIS monoclonal antibody (Novagen) for 1 h at room temperature.
Blots were washed extensively with TBST and incubated with horse-
radish peroxidase conjugated secondary antibody. After 1 h, blots
were washed as above and developed with an enhanced chemilumi-
nescence kit (Amersham).
2.5. Transfection and reporter assay
CHO cells were maintained in MEMK media supplemented with
10% fetal bovine serum, 50 U/ml penicillin and 50 Wg/ml streptomycin
at 37‡C in a humidi¢ed 5% atmosphere. Cells were seeded on 12 well
plates (Costar) with 1 ml media in each well. When reaching V80%
con£uence, the cells were switched to MEMK media containing 5%
lipoprotein de¢cient serum (LPDS) (Cocalico Biologicals) and main-
tained for 24 h before transfection using the lipofectamine mediated
method (Gibco BRL). The cells were transfected with the following
constructs: wild-type or mutant forms of TetR-LXRL LBD (0.05 Wg/
well), pTet-Luc (0.2 Wg/well) and pSV-L-gal (0.2 Wg/well) [21]. An
equal amount of DNA was used in each transfection using pcDNA3.1
as complement. Four h after incubated with the transfection mix, the
cells were washed and treated with 50 WM 24(S)-hydroxycholesterol
(dissolved in dimethyl sulfoxide, DMSO) or DMSO for 24 h in
MEMK medium plus 5% LPDS. The ¢nal DMSO concentration in
the medium did not exceed 0.2% (v/v). The cells were harvested with
lysis bu¡er provided by the luciferase or L-galactosidase (L-gal) assay
kit and enzyme assays were carried out according to the manufactur-
er’s manual (Promega).
3. Results and discussion
3.1. Identi¢cation of amino acid residues that may be involved
in ligand binding by LXRL
Previous work on PPARs, RXRK and RARQ has identi¢ed
functional helical regions that are involved in ligand binding,
among which helix 12 acts as a lid to close the binding pocket
and helix 3 is involved in ligand entry [14,15,22]. In PPARQ,
R288, E291 and E295 in helix 3 are major determinants of the
ligand entry site [22]. However, none of these amino acids are
conserved in LXRs or FXR (Fig. 1), which is consistent with
the fact that LXRs and FXR have ligands structurally distinct
from those for PPARs [8,9,23]. In addition, the glutamic acid
residue in PPARK corresponding to E291 in PPARQ has been
demonstrated to be important in ligand selectivity [17] (Fig.
1). However, the glutamic acid is only conserved in PPARs in
the alignment of helix 3 regions from LXRs, FXR and PPARs
(Fig. 1). Despite the structural di¡erence between their li-
gands, LXRs and PPARs do share conserved residues in their
helix 3 regions (Fig. 1), among which a phenylalanine (F268
in LXRL) and a valine (V279 in LXRL) are conserved across
all sequences. V279 in LXRL corresponds to V293 in PPARQ,
which is in proximity to residues R288, E291 and E295 at the
carboxyl terminus of helix 3, a region important for ligand
selectivity in PPARQ [22]. In contrast, F268 in LXRL is close
to the amino terminus of helix 3 and its role in ligand binding
has not been de¢ned. In addition, four residues are conserved
only in LXRs and FXR, including T272, E273, A275 and
Q280 in LXRL (Fig. 1). Among these residues, T272 is the
most amino terminal. To date, the importance of the carboxyl
half of helix 3 in ligand entry has been established [14,15,22].
Here we made mutations at F268 and T272 to identify the
roles of the conserved residues in the N-terminus of helix 3 in
LXRL.
3.2. Mutagenesis, expression and puri¢cation of LXRL LBD
To identify the roles of residues F268 and T272 in oxysterol
binding by LXRL, we made alanine replacement mutations at
F268 and T272 of LXRL LBD, respectively, and examined the
e¡ects on ligand binding and transcriptional activation.
An expression vector (pET-LXRL LBD) for human LXRL
LBD was constructed, in which the N-terminus of the LXRL
LBD was tagged with 10 polyhistidines. Both the wild-type
and the two mutant LBDs, designated F268A and T272A,
respectively, were expressed in E. coli. The expression levels
of the protein were similar as demonstrated by Western blot-
ting (Fig. 2A). The size of the identi¢ed protein is consistent
with the predicted molecular weight of LXRL LBD. We pu-
ri¢ed the wild-type and mutants with one step a⁄nity chro-
Fig. 1. Sequence alignment of helix 3 regions in the ligand entry do-
mains from LXRs, FXR and PPARs. The residues conserved in all
the nuclear receptors or only in the LXRs and FXR are highlighted.
The residues important in ligand selectivity as demonstrated in pre-
vious studies are outlined. The mutated residues in LXRL are indi-
cated by arrows.
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matography. The puri¢ed protein was resolved on a sodium
dodecyl sulfate (SDS) gel (Fig. 3A). We found that using a
washing bu¡er containing imidazole, the contaminating pro-
teins and RXR can by removed from the column. This allows
us to carry out a ligand binding assay with LXRL LBD alone.
3.3. Ligand binding assay with the wild-type and mutant LBDs
The bacterial lysates with wild-type and mutant LBDs, re-
spectively, were tested for ligand binding with [3H]24(S)-hy-
droxycholesterol. Mutant T272A still binds at a level similar
to the wild-type LBD, while F268A failed to bind [3H]24(S)-
hydroxycholesterol (Fig. 2B). These data suggest that residue
F268 is critical for ligand binding.
In order to examine ligand binding in the absence of RXR,
a ligand binding assay with the puri¢ed protein was carried
out. Mutant F268A does not bind ligand, consistent with the
data with lysates (Fig. 2B). However, mutant T272A still
binds but at a lower level than the wild-type (Fig. 3B). The
di¡erence in ligand binding by T272A in the lysate and in
puri¢ed form may be due to the presence of RXR. Alterna-
tively, it could be due to changes in protein folding during or
after protein puri¢cation. Nonetheless, these data suggest that
residue F268 is critical for ligand binding while residue T272
is not as important. The phenylalanine residue is conserved
across all the sequences in helix 3 regions of LXRs, PPARs
and FXR (Fig. 1). The e¡ect of the alanine replacement mu-
tation at F268 might be a general e¡ect on ligand binding
instead of being speci¢c for LXRs. Although residue T272
is unique to LXRs and FXR, it does not appear to be in-
volved in oxysterol speci¢c ligand binding.
3.4. Reporter assay with chimeric nuclear receptors
To further investigate the activities of mutants F268A and
T272A, we examined the transcriptional activation by wild-
type and mutant LXRL LBDs using a reporter system [21]. A
chimeric receptor was constructed with bacteria tetracycline
repressor (TetR) at the N-terminus and LXRL LBD at the
C-terminus. A luciferase reporter with a TetR binding site in
the promoter region (pTet-Luc) was used in the assay. The
wild-type TetR-LXRL LBD and the mutants were co-trans-
fected with the reporter pTet-Luc in CHO cells. The trans-
fected cells were treated with 24(S)-hydroxycholesterol or un-
treated and harvested for enzyme assay. When transfected
cells were not induced with LXRL ligand, the reporter activity
was minimal (Fig. 4). In the presence of ligand, the reporter
Fig. 2. E¡ects of point mutations on ligand binding using bacterial
lysates. A: Expression of wild-type and mutant LXRL LBDs in the
presence of RXR. Same amount of lysates from E. coli cells ex-
pressing wild-type LXRL LBD (lane 1), mutant F268A (lane 2) and
mutant T272A (lane 3), respectively, were resolved by SDS^polyac-
rylamide gel electrophoresis (PAGE) and transferred to membrane.
The membrane was probed with a monoclonal anti-HIS antibody
and developed non-isotopically (Section 2). B: Ligand binding assay
with the wild-type and mutant lysates. Same amount of lysates was
used for ligand binding assay. The ¢nal [3H]24(S)-hydroxycholester-
ol concentration was 200 nM. Values are mean þ S.D. (n = 3).
Fig. 3. E¡ects of point mutations on ligand binding using puri¢ed
proteins. A: Puri¢ed wild-type and mutant LXRL LBDs. Same
amount of wild-type LXRL LBD (lane 1), mutant F268A LBD
(lane 2) and mutant T272A LBD (lane 3), respectively, were re-
solved by SDS^PAGE. B: Ligand binding assay with puri¢ed pro-
tein as described in Fig. 2. Values are mean þ S.D. (n = 3).
Fig. 4. Transactivation of the pTet-luc reporter gene by chimeric re-
ceptors containing LXRL and mutant LBDs. CHO cells were transi-
ently transfected with reporter pTet-luc, wild-type (WT) or mutant
TetR-LXRL LBDs (F268A and T272A), and a L-galactosidase ex-
pression vector (pSV-L-gal) as internal control. No chimeric receptor
plasmid was included in the control group (Luc/Bgal). The trans-
fected cells were treated with 24(S)-hydroxycholesterol for 24 h and
harvested for luciferase and L-galactosidase assays (open bars,
treated; ¢lled bars untreated). The luciferase activity was normalized
with L-galactosidase activity and expressed in arbitrary units.
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activity was induced two-fold in cells transfected with TetR-
LXRL LBD (Fig. 4), suggesting that there is ligand dependent
activation of the reporter by TetR-LXRL LBD. In contrast,
there was no transcriptional activation of the reporter by the
TetR-LXRL LBD containing the F268A mutation in the pres-
ence or absence of ligand. This data suggests that mutant
F268A does not respond to the ligand and is not capable of
activating gene expression, which is consistent with the ligand
binding data (Figs. 2 and 3). In addition, TetR-LXRL LBD
containing mutation T272A still transactivates the reporter
(Fig. 4) in the presence of ligand, consistent with the ligand
binding data (Figs. 2 and 3). Therefore, mutation F268A af-
fects both ligand binding and transcriptional activation by
LXRL while mutation T272A has little e¡ect. It should be
noted that T272A has higher basal and activation activity
than the wild-type LBD. This could be due to a higher ex-
pression level of T272A. Nonetheless, the fold of activation by
this mutant in the presence of ligand is similar to that by the
wild-type LXRL LBD, suggesting that mutation at T272 did
not change ligand dependent activation of the reporter gene
expression.
Residue F268 is a conserved amino acid across all LXRs
and PPARs in the ligand entry domain. Its importance is less
likely speci¢c for LXRs but, instead, it could play a general
role in ligand binding. Thus, it may not be involved in ligand
selectivity. Rather, it may be involved in maintaining the
structure of the ligand binding pocket.
3.5. The 3D model
To further explore the helix 3 region and investigate the
roles of residues F268 and T272 in ligand binding by
LXRL, we built a 3D model of human LXRL based on the
published crystal structure of human PPARQ [22] and amino
acid sequence alignment (Fig. 5). Both F268 and T272 reside
in the helix 3 region of LXRL. The hydrophobic side group of
residue F268 faces the ligand binding pocket and might be
involved in the hydrophobic interaction with oxysterols. In
the meantime, F268 also faces the direction of the connecting
loop between helices 10 and 11 (AF2 domain). The long side
group of F268 may be required for keeping the binding pock-
et open by pushing the loop in the opposite direction. While
the side chain of T272 is shorter it is not required for this
function. Thus, removing the side chain of T272 by alanine
replacement did not a¡ect the size of the binding pocket,
whereas removing the hydrophobic side group of F268 re-
lieves the force keeping the connecting loop away from helix
3 and allows the connecting loop to move toward helix 3. As a
result, the opening of the binding pocket is smaller and ligand
Fig. 5. A 3D model of human LXRL. The model was built based on the sequence alignment of human LXRL and human PPARQ and the
crystal structure of human PPARQ. AF2 (helix 11), helices 1, 3 and 10 are indicated. Residues F268 and T272 in helix 3 are shown in atom to
illustrate their positions relative to the ligand binding pocket.
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entry might be prevented. The role of residue F268 in ligand
binding might be a combination of hydrophobic interaction
with ligands and maintaining the integrity of the binding
pocket structure. This is consistent with the fact that this res-
idue is conserved in LXRs, PPARs and FXR.
3.6. Conclusion
Using sequence alignment and 3D modeling, we have iden-
ti¢ed residues in the helix 3 region of LXRL LBD that might
be important for ligand binding. Site directed mutagenesis
studies demonstrated that residue F268 is critical for ligand
binding by LXRL while mutation at residue T272 does not
a¡ect ligand binding. These data are consistent with our ¢nd-
ings in cell based reporter assay using chimeric receptor con-
structs. In contrast to the previous mutations in PPARs that
change the ligand selectivity [17,24], alanine replacement at
F268 completely abolished ligand binding and ligand depen-
dent activation by LXRL. Our data is the ¢rst study that
identi¢es a critical residue for ligand binding and transcrip-
tional activation by LXRL and should provide insight into the
ligand dependent activation mechanism of LXRs.
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